Categories: Life Sciences

Toronto molecular diagnostics company Qvella raises $20 million U.S. Series A round

Toronto molecular diagnostics company Qvella has raised a $20 million (U.S.) Series A round of financing, led by RA Capital Management and Whitecap Venture Partners, with Hatteras Venture Partners and Sands Capital Ventures participating as syndicate partners.

“This latest round of funding provides us with the capital to support our ongoing research and development, and build out our team. It also gives us access to strong investment partners who will provide strategic guidance and back our future growth,” said Qvella CEO and co-founder Tino Alavie. “Our history with the Whitecap team, who led our first institutional financing, together with RA Capital Management’s experience and expertise in the healthcare and life sciences market, will prove incredibly beneficial as we pursue the opportunities that lie ahead.”

Founded in 2009 by a group of scientists and engineers, Qvella aims to reduce time to results in bacteriology using its Field Activated Sample Treatment (FAST) technology, which enables the rapid detection of infectious agents in a blood sample.

The solution helps to solve the problem of over-prescription of antibiotics, which has had an overall bad effect on the population for several decades now.

Typically, a physician needs to wait 24 to 72 hours while a sample is analyzed in a lab before knowing whether a patient is actually infected.

“Solutions that enable patients to receive the right treatment quickly will fulfill a key unmet need in microbiology,” says Qvella board member and executive in residence at RA Capital Management Parker Cassidy. “Qvella has the perfect combination of technology, team, and potential to impact how antibiotics are delivered and developed.”

For some patients, a delayed diagnosis can be deadly, especially if their condition is sepsis, a blood infection that is the second-leading in-hospital cause of death among critical patients, affecting a quarter of patients in intensive care units.

In concert with most medical centres’ Antibiotic Stewardship programs, Qvella’s technology can speed up one part of the process, enabling timely clinical decisions, thereby reducing hospital stays and reducing overall treatment costs.

“Qvella is on an accelerated path to significantly change how bacteriology is handled in the healthcare system,” says Blaine Hobson, of Whitecap Venture Partners. “This latest round of funding will play an important role in enabling Qvella to achieve its vision, and at the same time strengthens our investment in the MedTech market.”

Qvella will use the financing for ongoing product development and expand its team.

Tagged with: qvella
Terry Dawes

Recent Posts

Can you make money with Metatek-Group stock?

Metatek-Group’s (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) strong sequential revenue growth and expectations for a further improvement in… [Read More]

2 hours ago

Ascend Wellness Holdings: Buy, Sell or Hold?

Ascend Wellness Holdings’ (Ascend Wellness Holdings Stock Quote, Chart, News, Analysts, Financials CSE:AAWH.U) return to year-over-year revenue growth and improving… [Read More]

2 hours ago

RBC raises price target on Tidewater Renewables to $31.00

RBC Capital Markets analyst Maurice Choy raised his target on Tidewater Renewables (Tidewater Renewables Stock Quote, Chart, News, Analysts, Financials… [Read More]

2 hours ago

Apotex Health: this analyst just raised his price target

RBC Capital Markets analyst Douglas Miehm raised his target for Apotex Health (Apotex Health Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 hours ago

Magellan Aerospace: Buy, Sell or Hold?

Magellan Aerospace’s (Magellan Aerospace Corp. Stock Quote, Chart, News, Analysts, Financials TSX:MAL) stronger-than-expected third-quarter results and potential opportunities from increased… [Read More]

3 hours ago

Is Cargojet (TSX:CJT) a buy right now?

Cargojet's (Cargojet Stock Quote, Chart, News, Analysts, Financials TSX:CJT) stronger-than-expected third-quarter results and ability to maintain margins despite higher fuel… [Read More]

3 hours ago